Clinical Trial Update: A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies [Phase 1, Phase 2]

View source ↗

Summary

IDP-121 is being studied in a Phase 1/2 trial for relapsed/refractory hematologic malignancies and is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Diffuse Large B-cell Lymphoma
• Double-hit Lymphoma
• High-grade B-cell Lymphoma Nos
• Multiple Myeloma
• Triple-hit Lymphoma

Drugs mentioned

• IDP-121 (IDP-121)

Snippet

Sponsor: IDP Discovery Pharma S.L. | Conditions: Multiple Myeloma (MM), Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Phase 1, Phase 2 | Status: RECRUITING